Det kommer mer info....................................

In 2011, AREVA Med received authorization from the United States Food and Drug Administration (FDA) to begin clinical trials of ²¹²Pb-TCMC-Trastuzumab

In 2018 .Nordic Nanovector : The goal of this project is to start the Development of a new treatment for chronic lymphocytic leukemia (CLL). The primary objective of this project is to complete a phase 1 study with the new alpha-particle emitting radioimmunoconjugate 212Pb-TCMC-NNV003.

Roy sørger for at verdiene øker..........................

Publication number: 20190008989
Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
Type: Application
Filed: June 13, 2018
Publication date: January 10, 2019
Inventors: Roy H. Larsen, Ada Repetto-Llamazares

At Lymrit 37/05 er ferdig innrulert i juni var kontraktsfestet. Ferdig snakket. Ledelsen holder på med flere produkter i pipelinen og dette vet Bravo

Grants from : Novartis, Amgen, Roche/Genentech, Regeneron, Chugai, Synthon, AstraZeneca, Radius Health, CytomX Therapeutics and Nordic Nanovector, all to the hospital for high-dose chemotherapy with hematopoietic stem cell transplantation in high-risk breast cancer

https://clinicaltrials.gov/ct2/show/NCT03087409

Jostein vet mye om forskning på brystkreft og her er en studie av Helen Heyerdahl. Hvilket produkt i pipelinen tenker de å bruke mot f.eks brystkreft og eggstokkreft og andre kreftformer mon tro.................... Noen skribenter som vet om dette ?

https://www.researchgate.net/publication/49718931_Treatment_of_HER2-Expressing_Breast_Cancer_and_Ovarian_Cancer_Cells_With_Alpha_Particle-Emitting_227Th-Trastuzumab

WHAT HAS BEEN DISCUSSED AT ASCO19 SESSION.............................. ARE WE READY FOR PRIME TIME IN MOLECULAR IMAGING IN BREAST CANCER ?

Husk å koble inn SL. Bruk gearing og belåning så kommer naboen til å rappe aksjene billigere og billigere.
---------------------------------------------
Lagt til kl 17.08
Project group "Targeted alpha therapy"
Metastases in bones, lymph nodes and lungs are common challenges among oncology patients (e.g. breast cancer, prostate cancer, osteosarcoma) and are the primary cause of death. Efficacious new treatment options are sorely needed. Alpha-particle emitting radionuclides being highly cytotoxic may fulfil this critical need. We study a novel technology with potentially broad therapeutic applications for cancer micrometastases by means of dual targeted alpha particle radiation. The treatment involves administration of a bone-seeking, alpha-particle emitting radionuclide 224Ra and its daughter radionuclide 212Pb solution containing chelator-labelled new and existing molecular ligands and tumour-associated monoclonal antibodies (mAb) as carriers for the daughter radionuclide. Pb-212 is a source of highly cytotoxic alpha particles via its decay to 212Bi daughter.

Contact information
Asta Juzeniene, Scientist, Ph.D.
Department of Radiation Biology, Institute for Cancer Research
The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway

Oslo, Norway, 11 July 2019

Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been
…

Vis børsmeldingen
enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan
-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma
(DLBCL) not eligible for stem cell transplantation.

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation
study designed to assess the safety, tolerability, pharmacokinetic profile and
preliminary anti-tumour activity of a single administration of Betalutin®.
Patients were enrolled at clinical trial sites in the US and Europe. More
information on this study can be found at www.clinicaltrials.gov (NCT02658968).
Preliminary results are expected in the second half of 2019.

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up
to 43% of all NHL cases, making it the most common form of the disease.
Approximately 40% of DLBCL patients relapse after first-line combination
treatment with rituximab and chemotherapy and only 30-40% of relapsed patients
respond with subsequent high-dose chemotherapy followed by Stem Cell
Transplantation (ref. 1 below). There are currently very few therapeutic options
for patients not eligible for SCT, which makes relapsed DLBCL a serious unmet
medical need. The number of diagnosed cases of DLBCL in the US and Europe in
2016 was 26,500 and 17,200, respectively. These numbers are expected to reach
31,500 (US) and 19,000 (Europe) by 2024 (ref. 2 below).

Lisa Rojkjaer, Chief Medical Officer at Nordic Nanovector, said: “We are
delighted to have reached this important milestone and look forward to the
preliminary results during the second half of the year. Planning is underway for
an expansion cohort to further assess safety and efficacy in this challenging to
treat patient population. We expect more patients to be enrolled when the best
dose is selected from the first part of the study.”

References

L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse
large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66-70

Non-Hodgkin’s Lymphoma (2015) Decision Resources

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

Frontmasta
Ledelsen vet åpenbart mer enn aksjonærene. Spørsmålet er om det har betydning for verdien av selskapet. Dersom det har det så bør vi få en børsmelding. Antar at de tenker at aksjonærene kan trenge noe tid på å fordøye en slik melding og at meldingen derfor kommer utenfor børsens åpningstid.

Jepp det er noe dritt, når ledelsen sitter på veldig mye info som de ikke vil dele med aksjemarkedet. Man finner da info på Internett...............

The pharma industry is built on confidential information that must be protected, and this is how to solve an under-table agreement with 3P Biopharmaceuticals

http://fjb.pt/services/

Vi hørte vel aldri noe fra Jostein sin tur til München heller?

Ahhh.. NANO og BRAVO - det er kjeeeedeliiiig med lite nytt!!

Ikke mange analytikere som evner å følge grave virksomheten din hverken gjennom agurktida eller forøvrig..

Har dere info om hvorfor Jostein besøkte Maria Gonzales Pajuelo tidlige i år ? Skulle han se på den nye tapeten og de nye gardinene.........eller skulle de diskutere NNV020 - chimeric anti-CD37 antibody

Hun skal presentere senere i år : The Journey to the Antibody : Tailoring for Success

María González Pajuelo, CSO, FairJourney Biologics

To maximize the possibility to select “the” antibody, at FJB we have taken antibody discovery to an unprecedented level by creating a versatile toolbox that allows the selection by phage display of antibody fragments of different species from large naïve and immune repertoires. Ultimately, these fragments can be engineered and converted to mono- and bi-specific formats that are produced in CHO cells.

Farmaindustrial Spain skriver : 3P Biopharmaceuticals og Nordic Nanovector har utvidet sin samarbeidsavtale for utvikling av Betalutin, med fokus på behandling av non-Hodgkin lymfom.

BRAVO............ FÅ FINGEN UT OG FORKLARE

Vedrørende søknad fra Nordic Nanovector ang nye museforsøk, som ble godkjent av Mattilsynet - juni 2018 står det å lese.........De nyutviklede stoffproduktene og terapikombinasjonene som involverer disse produktene, vil potensielt ha større effektivitet og færre bivirkninger enn de tilgjengelige produktene i dag.

https://www.mattilsynet.no/dyr_og_dyrehold/dyrevelferd/forsoksdyr/forsoksdyrsoknader/therapy_and_toxicity_of_nnv_therapy_candidates_in_combination_with_other_anticancer_treatments.33438

Tenker at et av produktene som ble forsket på har fått benevnelsen NNV020. Kommer det flere nye ........NNV 021 osv ? Eller plukket de frem det beste NNV020. Hva det skal brukes til burde ledelsen opplyst om, eller er det så spesielt og banebryterne................

Arne og Jostein, Ada og andre forskere stopper ikke før alle kreftcellene er døde.

Se videoen.

https://nanolive.ch/adc-trigger-nbe-therapeutics/

TAR NETTLØKENE FERIE ELLER SKAL DE TRADE .....................................................................

Det kan virke som nano har valgt å sende søke endelig godkejnning av patentet for alt som har med nhl og betalutin å gjøre og ofte gjør det jo dette når det nærmer seg kommersialisering? Det nærmer seg ihvertfall ett slags gjennonbrudd. Men big ph kommer ikke til å la nano få spise markedsandeler av dette markedet. Novartis bayer og roche i budkrig

Merkelig artikkel la jeg også merke til.

Prosjektet til Simone Mester ble tatt opp i UiO: Livsvitenskaps innovasjonsprogram SPARK Norway i januar 2018.
Videre uttesting og råd fra mentorer skal bidra til at prosjektet fører frem anvendelse.

https://www.uio.no/forskning/satsinger/livsvitenskap/innovasjon/historier/antistoffer-kreftmedisin.html


Så kan man tenke på hva resultatene ble.................... Måtte Jostein fikse på patentsøknaden ved fjerne claim 2-28 med noe nytt ( 29 - 41 ) som nå omhandler timer og dager mv

Date Published. June 27, 2019 - Inventors Jostein Dahl

Publication Number - 20190192703

https://trea.com/information/treatment-of-non-hodgkin-lymphoma-using-lilotomab-and-177lu-lilotomab-satetraxet/patentapplication/70be05ae-3a4a-43ee-971d-e4f23cbaf5dd

De forsker for å få bedre resultater i studiene...............................................

Tja...

«The launch of new drugs in the near future expected to support the growth of non-hodgkins lymphoma treatment market. For instance, a new drug Axicabtagene ciloleucel, received priority review status to get commercialize for the treatment of non-hodgkins lymphoma as a second line therapy. This drug is expected to launch in later of year 2017.»

Kan virke som artikkelen er gammel selv om det står at den ble publisert i går.

Men hyggelig å bli nevnt i det selskapet der.